Alpha Cognition Inc (ACOG)

$5.95 +0.46 (8.38%)
Market Cap 129.56M
Revenue (ttm) 10.22M
Net Income (ttm) -20.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -202.25%
Debt to Equity Ratio 0.00
Volume 45,652
Avg Vol 53,210
Day's Range N/A - N/A
Shares Out 21.77M
Stochastic %K 3%
Beta 2.38
Analysts Strong Sell
Price Target $16.00

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatit...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 564 9244
Address:
750 West Pender Street, Suite 1200, Vancouver, Canada
Bioinvester001
Bioinvester001 May. 13 at 3:10 PM
$ACOG Bullish, but really tired of these legacy investors selling at every turn.
0 · Reply
RunningRobert1
RunningRobert1 May. 5 at 11:52 AM
$ACOG This Unknown Pharma Stock Has A Shot At Breakeven - Alpha Cognition https://youtu.be/qUb5X2FKRTI Def a little known biotech company, they have 1 approved product, small cash burn, and a chance to break even in 2027, this is def something for the watchlist!
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 2:24 PM
$ACOG
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 30 at 11:53 PM
$ACOG RSI: 48.86, MACD: 0.0866 Vol: 0.39, MA20: 6.50, MA50: 6.06 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 28 at 9:40 PM
$ACOG https://www.businesswire.com/news/home/20260428200818/en/Alpha-Cognition-Nasdaq-ACOG-to-Report-First-Quarter-2026-Financial-Results-and-Provide-Business-Update-on-Thursday-May-14-2026 -Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close- - The live audio webcast will be accessible here: https://viavid.webcasts.com/starthere.jsp?ei=1761279&tp_key=1a22b7db8e
1 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 27 at 11:06 PM
$ACOG https://www.businesswire.com/news/home/20260427777982/en/Alpha-Cognition-Inc.-to-Participate-in-Three-Upcoming-Investor-Conferences
0 · Reply
Bioinvester001
Bioinvester001 Apr. 22 at 6:18 PM
$ACOG New board member has BO experience and skills. McFadden playbook in motion here. Looking for a grind up in the sp to earnings date.
0 · Reply
gnarled15
gnarled15 Apr. 20 at 12:34 PM
$ACOG 😁 $7 🤫
0 · Reply
JackCampbell
JackCampbell Apr. 17 at 7:42 PM
$ACOG Craig-Hallum initiated coverage on Alpha Cognition Inc (NASDAQ:ACOG) with a buy rating and a price target of $14.00, the firm said Thursday.
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 16 at 8:11 PM
$ACOG https://www.businesswire.com/news/home/20260415562909/en/Alpha-Cognition-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
0 · Reply
Latest News on ACOG
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Apr 28, 2026, 4:30 PM EDT - 15 days ago

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Apr 27, 2026, 8:00 AM EDT - 16 days ago

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Apr 20, 2026, 5:00 PM EDT - 23 days ago

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Craig-Hallum bullish on Alpha Cognition, initiates with a Buy

2026-04-17T12:11:39.000Z - 26 days ago

Craig-Hallum bullish on Alpha Cognition, initiates with a Buy

Alpha Cognition initiated with a Buy at Craig-Hallum

2026-04-17T11:38:54.000Z - 26 days ago

Alpha Cognition initiated with a Buy at Craig-Hallum

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2026, 8:00 PM EDT - 27 days ago

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition granted U.S. patent for ALPHA-1062 in brain injury

2026-04-01T20:37:03.000Z - 6 weeks ago

Alpha Cognition granted U.S. patent for ALPHA-1062 in brain injury

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Apr 1, 2026, 4:30 PM EDT - 6 weeks ago

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Apr 1, 2026, 9:51 AM EDT - 6 weeks ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Biotech Alert: Searches spiking for these stocks today

2026-03-30T16:21:02.000Z - 6 weeks ago

Biotech Alert: Searches spiking for these stocks today

IBIO

Alpha Cognition Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 6 weeks ago

Alpha Cognition Earnings Call Transcript: Q4 2025

Alpha Cognition reports FY25 EPS ($1.17) vs. ($2.04) last year

2026-03-26T20:05:39.000Z - 6 weeks ago

Alpha Cognition reports FY25 EPS ($1.17) vs. ($2.04) last year

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Mar 26, 2026, 4:01 PM EDT - 6 weeks ago

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Mar 13, 2026, 1:46 PM EDT - 2 months ago

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Mar 10, 2026, 8:30 AM EDT - 2 months ago

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Biotech Alert: Searches spiking for these stocks today

2026-02-26T16:50:34.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

Alpha Cognition enrolls first patient in BEACON trial

2026-02-25T13:58:16.000Z - 2 months ago

Alpha Cognition enrolls first patient in BEACON trial

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Feb 25, 2026, 8:30 AM EST - 2 months ago

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition announces issuance of U.S. patent for Zunveyl dosing

2026-02-18T14:21:20.000Z - 3 months ago

Alpha Cognition announces issuance of U.S. patent for Zunveyl dosing

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Feb 18, 2026, 8:30 AM EST - 3 months ago

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Biotech Alert: Searches spiking for these stocks today

2026-02-13T16:35:22.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

Biotech Alert: Searches spiking for these stocks today

2026-02-11T16:45:40.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

Biotech Alert: Searches spiking for these stocks today

2026-01-16T17:10:23.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Jan 7, 2026, 4:30 PM EST - 4 months ago

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Alpha Cognition Transcript: Fireside Chat

Dec 2, 2025, 12:00 PM EST - 5 months ago

Alpha Cognition Transcript: Fireside Chat

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Dec 1, 2025, 5:51 PM EST - 5 months ago

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Nov 14, 2025, 9:46 AM EST - 6 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Alpha Cognition Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 6 months ago

Alpha Cognition Earnings Call Transcript: Q3 2025

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:00 PM EST - 6 months ago

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Alpha Cognition price target lowered to $18 from $20 at H.C. Wainwright

2025-10-20T12:26:52.000Z - 7 months ago

Alpha Cognition price target lowered to $18 from $20 at H.C. Wainwright

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Oct 14, 2025, 4:30 PM EDT - 7 months ago

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Alpha Cognition Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Oct 6, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Alpha Cognition 5.6M share Spot Secondary priced at $6.25

2025-10-01T09:45:13.000Z - 8 months ago

Alpha Cognition 5.6M share Spot Secondary priced at $6.25

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Sep 30, 2025, 11:14 PM EDT - 8 months ago

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Alpha Cognition announces common stock offering, no amount given

2025-09-30T21:00:14.000Z - 8 months ago

Alpha Cognition announces common stock offering, no amount given

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Sep 30, 2025, 4:58 PM EDT - 8 months ago

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Aug 28, 2025, 1:00 PM EDT - 9 months ago

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Alpha Cognition files $250M mixed securities shelf

2025-08-22T20:05:17.000Z - 9 months ago

Alpha Cognition files $250M mixed securities shelf

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Aug 15, 2025, 5:10 PM EDT - 9 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Alpha Cognition Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Alpha Cognition Earnings Call Transcript: Q2 2025

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Alpha Cognition announces CMS Zunveyl NDA accepted for review by NMPA

2025-07-29T13:01:07.000Z - 10 months ago

Alpha Cognition announces CMS Zunveyl NDA accepted for review by NMPA

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Jul 29, 2025, 8:30 AM EDT - 10 months ago

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Alpha Cognition files to sell 2.09M common shares for holders

2025-07-21T21:35:33.000Z - 10 months ago

Alpha Cognition files to sell 2.09M common shares for holders

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Alpha Cognition shares preclinical data for TBI drug ALPHA-1062

2025-07-01T21:15:09.000Z - 11 months ago

Alpha Cognition shares preclinical data for TBI drug ALPHA-1062

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Jul 1, 2025, 5:05 PM EDT - 11 months ago

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition files to sell 2.375M common shares for holders

2025-07-01T20:41:18.000Z - 11 months ago

Alpha Cognition files to sell 2.375M common shares for holders

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

May 19, 2025, 10:25 AM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Alpha Cognition Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings Call Transcript: Q1 2025

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

May 15, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

May 1, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Apr 10, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Apr 1, 2025, 4:27 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings Call Transcript: Q4 2024

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Feb 12, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 30, 2025, 11:05 AM EST - 1 year ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Alpha Cognition Transcript: Investor Update

Jan 28, 2025, 4:00 PM EST - 1 year ago

Alpha Cognition Transcript: Investor Update

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Jan 14, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Jan 8, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Jan 6, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Dec 16, 2024, 2:56 PM EST - 1 year ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Dec 16, 2024, 11:51 AM EST - 1 year ago

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Alpha Cognition Announces Voluntary Delisting from CSE

Dec 12, 2024, 6:41 PM EST - 1 year ago

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Nov 15, 2024, 5:00 PM EST - 1 year ago

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Nov 12, 2024, 9:22 AM EST - 1 year ago

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Bioinvester001
Bioinvester001 May. 13 at 3:10 PM
$ACOG Bullish, but really tired of these legacy investors selling at every turn.
0 · Reply
RunningRobert1
RunningRobert1 May. 5 at 11:52 AM
$ACOG This Unknown Pharma Stock Has A Shot At Breakeven - Alpha Cognition https://youtu.be/qUb5X2FKRTI Def a little known biotech company, they have 1 approved product, small cash burn, and a chance to break even in 2027, this is def something for the watchlist!
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 2:24 PM
$ACOG
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 30 at 11:53 PM
$ACOG RSI: 48.86, MACD: 0.0866 Vol: 0.39, MA20: 6.50, MA50: 6.06 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 28 at 9:40 PM
$ACOG https://www.businesswire.com/news/home/20260428200818/en/Alpha-Cognition-Nasdaq-ACOG-to-Report-First-Quarter-2026-Financial-Results-and-Provide-Business-Update-on-Thursday-May-14-2026 -Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close- - The live audio webcast will be accessible here: https://viavid.webcasts.com/starthere.jsp?ei=1761279&tp_key=1a22b7db8e
1 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 27 at 11:06 PM
$ACOG https://www.businesswire.com/news/home/20260427777982/en/Alpha-Cognition-Inc.-to-Participate-in-Three-Upcoming-Investor-Conferences
0 · Reply
Bioinvester001
Bioinvester001 Apr. 22 at 6:18 PM
$ACOG New board member has BO experience and skills. McFadden playbook in motion here. Looking for a grind up in the sp to earnings date.
0 · Reply
gnarled15
gnarled15 Apr. 20 at 12:34 PM
$ACOG 😁 $7 🤫
0 · Reply
JackCampbell
JackCampbell Apr. 17 at 7:42 PM
$ACOG Craig-Hallum initiated coverage on Alpha Cognition Inc (NASDAQ:ACOG) with a buy rating and a price target of $14.00, the firm said Thursday.
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 16 at 8:11 PM
$ACOG https://www.businesswire.com/news/home/20260415562909/en/Alpha-Cognition-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
0 · Reply
JackCampbell
JackCampbell Apr. 8 at 9:35 AM
$ACOG very
0 · Reply
SocioCobb
SocioCobb Apr. 7 at 3:14 PM
$ACOG watching this closely. Sitting at a critical resistance/support level. Close here or higher wpuld be bullish for continuing gains. S4 Open matket about 8 mos ago 20% higher- hmmmm
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Apr. 2 at 7:35 AM
$ACOG https://www.businesswire.com/news/home/20260401736131/en/Alpha-Cognition-Receives-Issued-U.S.-Patent-for-ALPHA-1062-for-Treatment-of-Traumatic-Brain-Injury
0 · Reply
focafoca99
focafoca99 Apr. 1 at 9:51 PM
$ACOG picked up a new U.S. patent around ALPHA-1062 for traumatic brain injury, which helps extend the IP story beyond Alzheimer's.
0 · Reply
jumptime
jumptime Apr. 1 at 9:33 PM
$ACOG BRIEF-Alpha Cognition Receives Issued U.S. Patent For Alpha-1062 For Treatment Of Traumatic Brain Injury
0 · Reply
LewisDaKat
LewisDaKat Apr. 1 at 7:00 PM
$ACOG Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425 https://marketwirenews.com/stock/acog/news/stonegate-capital-partners-updates-coverage-on-alpha-5505211532967784.html?utm_source=stocktwits
0 · Reply
LewisDaKat
LewisDaKat Apr. 1 at 6:30 PM
$ACOG Alpha Cognition (ACOG) Q4 2025 Earnings Transcript https://marketwirenews.com/stock/acog/news/alpha-cognition-acog-q4-2025-earnings-transcript-6348690691221924.html?utm_source=stocktwits
0 · Reply
newsfile_corp
newsfile_corp Apr. 1 at 1:52 PM
https://nfne.ws/290861 $ACOG @reportablenews #NASDAQ #Investing
0 · Reply
Bioinvester001
Bioinvester001 Mar. 31 at 5:02 PM
$ACOG Sleep disorders is the new big pharma focus. Acog addresses this with it's ALZ drug, and look for more interest in the company.
0 · Reply
jumptime
jumptime Mar. 31 at 3:04 PM
$ACOG Volume...
0 · Reply
rombrento
rombrento Mar. 30 at 9:47 PM
$ACOG
0 · Reply